keyword
MENU ▼
Read by QxMD icon Read
search

Everolimus AND aging

keyword
https://www.readbyqxmd.com/read/27928256/one-year-outcome-of-everolimus-eluting-stents-versus-biolimus-eluting-stents-in-patients-undergoing-percutaneous-coronary-intervention
#1
Mohammad Alidoosti, Vahideh Sharifnia, Seyed Ebrahim Kassaian, Alimohammad Hajizeinali, Hamidreza Poorhosseini, Mojtaba Salarifar, Younes Nozari, Elham Hakki Kazazi
Background: The biolimus-eluting stent (BES), with a biodegradable polymer, has not been previously compared with the everolimus-eluting stent (EES), as a second-generation drug-eluting stent (DES).We sought to compare the 1-year outcome between the PROMUS(™) stent (EES type) and the BioMatrix(™) stent (BES type). Methods: From March 2008 to September 2011, all patients treated with the PROMUS™ stent or the BioMatrix™ stent for coronary artery stenosis at Tehran Heart Center were enrolled. The primary end points were 1-year adverse events, comprising death, myocardial infarction, target vessel revascularization, and target lesion revascularization...
April 13, 2016: Journal of Tehran Heart Center
https://www.readbyqxmd.com/read/27918762/alternating-treatment-with-pazopanib-and-everolimus-vs-continuous-pazopanib-to-delay-disease-progression-in-patients-with-metastatic-clear-cell-renal-cell-cancer-the-ropetar-randomized-clinical-trial
#2
Geert A Cirkel, Paul Hamberg, Stefan Sleijfer, Olaf J L Loosveld, M Wouter Dercksen, Maartje Los, Marco B Polee, Franchette van den Berkmortel, Maureen J Aarts, Laurens V Beerepoot, Gerard Groenewegen, Martijn P Lolkema, Metin Tascilar, Johanna E A Portielje, Frank P J Peters, Heinz-Josef Klümpen, Vincent van der Noort, John B A G Haanen, Emile E Voest
Importance: To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. Objective: To test our hypothesis that an 8-week rotating treatment schedule with pazopanib and everolimus delays disease progression, exhibits more favorable toxic effects, and improves quality of life when compared with continuous treatment with pazopanib. Design, Setting, and Participants: This was an open-label, randomized (1:1) study (ROPETAR trial)...
December 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893038/targeting-the-pi3k-akt-mtor-pathway-for-the-treatment-of-mesenchymal-triple-negative-breast-cancer-evidence-from-a-phase-1-trial-of-mtor-inhibition-in-combination-with-liposomal-doxorubicin-and-bevacizumab
#3
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, Thorunn Helgason, Daniel D Karp, Funda Meric-Bernstam, Kenneth R Hess, Shelley M Herbrich, Vicente Valero, Constance Albarracin, Jennifer K Litton, Mariana Chavez-MacGregor, Nuhad K Ibrahim, James L Murray, Kimberly B Koenig, David Hong, Vivek Subbiah, Razelle Kurzrock, Filip Janku, Stacy L Moulder
Importance: Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response. Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy...
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27878332/accelerated-cardiac-rhabdomyoma-regression-with-everolimus-in-infants-with-tuberous-sclerosis-complex
#4
Fatou Aw, Isabelle Goyer, Marie-Josée Raboisson, Christine Boutin, Philippe Major, Nagib Dahdah
Tuberous sclerosis complex is associated with benign tumors such as cardiac rhabdomyomas (RHM) caused by the disinhibition of the mammalian target of rapamycin (mTOR) protein. Recent reports on everolimus, an mTOR inhibitor, have shown size reduction of RHM. We compared cases recently treated with everolimus to historic controls whose first echocardiography was within first month of life. The largest dimension of the largest RHM was reported as a percentage compared to the earliest echocardiography study. Treatment of the four cases was started at a median age of 6...
November 23, 2016: Pediatric Cardiology
https://www.readbyqxmd.com/read/27860334/maintenance-therapy-with-everolimus-for-subependymal-giant-cell-astrocytoma-in-patients-with-tuberous-sclerosis-the-eminents-study
#5
Joanna Trelinska, Iwona Dachowska, Dobromila Baranska, Konrad Stawiski, Katarzyna Kotulska, Wojciech Fendler, Sergiusz Jozwiak, Wojciech Mlynarski
OBJECTIVE: One of the therapeutic options for patients with tuberous sclerosis (TCS) and subependymal giant cell astrocytoma (SEGA) is everolimus treatment once daily, every day, to attain trough concentrations of 5-15 ng/ml (standard treatment). The aim of this study was to evaluate the efficacy and safety of a reduced dose of everolimus (three times a week with a daily dose as in standard treatment-maintenance therapy) in a group of patients who were previously treated with standard dose for at least 12 months...
November 15, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27815344/sealing-intermediate-nonobstructive-coronary-saphenous-vein-graft-lesions-with-drug-eluting-stents-as-a-new-approach-to-reducing-cardiac-events-a-randomized-controlled-trial
#6
Josep Rodés-Cabau, Sanjit S Jolly, John Cairns, Samer Mansour, Philippe L L'Allier, Patrick J Teefy, John J Graham, Michel R Le May, Warren J Cantor, David Wood, Kumar Balasubramanian, Robert DeLarochellière, Vlad Dzavik
BACKGROUND: The objective of this study was to assess the efficacy of sealing intermediate nonobstructive coronary saphenous vein graft (SVG) lesions with drug-eluting stents (DES; paclitaxel- or everolimus-eluting stents) for reducing major adverse cardiac events (MACE). METHODS AND RESULTS: This was a randomized controlled multicenter clinical trial that enrolled patients with a previous coronary artery bypass graft who had developed at least 1 intermediate nonobstructive SVG lesion (30%-60% diameter stenosis by visual estimation)...
November 2016: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/27809914/efficacy-and-safety-of-everolimus-in-children-with-tsc-associated-epilepsy-pilot-data-from-an-open-single-center-prospective-study
#7
Sharon Samueli, Klaus Abraham, Anastasia Dressler, Gudrun Gröppel, Angelika Mühlebner-Fahrngruber, Theresa Scholl, Gregor Kasprian, Franco Laccone, Martha Feucht
BACKGROUND: Epilepsy occurs in up to 90 % of all individuals with tuberous sclerosis complex (TSC). In 67 % disease onset is during childhood. In ≥ 50 % seizures are refractory to currently available treatment options. The mTOR-Inhibitor Everolimus (Votubia®) was approved for the treatment of subependymal giant cell astrocytoma (SEGA) and renal angiomyolipoma (AML) in Europe in 2011. It's anticonvulsive/antiepileptic properties are promising, but evidence is still limited. Study aim was to evaluate the efficacy and safety of Everolimus in children and adolescents with TSC-associated epilepsies...
November 3, 2016: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/27806902/very-thin-strut-biodegradable-polymer-everolimus-eluting-and-sirolimus-eluting-stents-versus-durable-polymer-zotarolimus-eluting-stents-in-allcomers-with-coronary-artery-disease-bio-resort-a-three-arm-randomised-non-inferiority-trial
#8
Clemens von Birgelen, Marlies M Kok, Liefke C van der Heijden, Peter W Danse, Carl E Schotborgh, Martijn Scholte, R Melvyn Tjon Joe Gin, Samer Somi, K G van Houwelingen, M G Stoel, Frits H A F de Man, J Hans W Louwerenburg, Marc Hartmann, Paolo Zocca, Gerard C M Linssen, Job van der Palen, Carine J M Doggen, Marije M Löwik
BACKGROUND: In patients with coronary artery disease, treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer might delay arterial healing. Novel very thin strut biodegradable polymer stents, which leave only a bare metal stent after polymer resorption, might improve long-term outcome. We investigated in allcomers the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarolimus, often clinically used but never compared, of which the biodegradable polymer everolimus-eluting stent was never before assessed in allcomers...
November 26, 2016: Lancet
https://www.readbyqxmd.com/read/27806897/comparison-of-an-everolimus-eluting-bioresorbable-scaffold-with-an-everolimus-eluting-metallic-stent-for-the-treatment-of-coronary-artery-stenosis-absorb-ii-a-3-year-randomised-controlled-single-blind-multicentre-clinical-trial
#9
Patrick W Serruys, Bernard Chevalier, Yohei Sotomi, Angel Cequier, Didier Carrié, Jan J Piek, Ad J Van Boven, Marcello Dominici, Dariusz Dudek, Dougal McClean, Steffen Helqvist, Michael Haude, Sebastian Reith, Manuel de Sousa Almeida, Gianluca Campo, Andrés Iñiguez, Manel Sabaté, Stephan Windecker, Yoshinobu Onuma
BACKGROUND: No medium-term data are available on the random comparison between everolimus-eluting bioresorbable vascular scaffolds and everolimus-eluting metallic stents. The study aims to demonstrate two mechanistic properties of the bioresorbable scaffold: increase in luminal dimensions as a result of recovered vasomotion of the scaffolded vessel. METHODS: The ABSORB II trial is a prospective, randomised, active-controlled, single-blind, parallel two-group, multicentre clinical trial...
November 19, 2016: Lancet
https://www.readbyqxmd.com/read/27798900/what-characterizes-long-term-survivors-of-recurrent-ovarian-cancer-case-report-and-review-of-the-literature
#10
Ziad Hilal, Beate Schultheis, Franziska Hartmann, Askin Dogan, Cem Cetin, Harald Krentel, Sven Schiermeier, Clemens B Tempfer
BACKGROUND: Women with recurrent ovarian cancer have a poor prognosis and short survival. However, some women are long-term survivors and it is unclear whether they share specific common characteristics. CASE REPORT: We present the case of a 63-year-old woman with histologically-proven recurrent ovarian cancer and a survival time of 16 years after the diagnosis of recurrence. She underwent initial debulking surgery in 1994, followed by 6 cycles of adjuvant chemotherapy with cisplatin and paclitaxel...
October 2016: Anticancer Research
https://www.readbyqxmd.com/read/27798513/longitudinal-pharmacokinetics-of-everolimus-when-combined-with-low-level-of-tacrolimus-in-elderly-renal-transplant-recipients
#11
Elias David-Neto, Fabiana Agena, Fernanda Ramos, Ana Heloisa Triboni, Paschoalina Romano, Persio de Almeida Rezende Ebner, Venceslau Coelho, Nelson Zocoler Galante, Francine Carvalinho Lemos
BACKGROUND: Although the proportion of elderly patients among renal transplant recipients has increased, pharmacokinetic (PK) studies of immunosuppressants rarely include older patients. METHODS: We studied 12-hours everolimus (EVL) PK in 16 elderly renal transplant recipients (all caucasians; 10 males; mean age, 64±2 years, (61-71y), in 4 separate time-points (at 7, 30, 60 and 150 days) after EVL introduction, corresponding to a mean post renal-transplantation day: PK1 (43±4days), PK2 (65±7 days), PK3 (106±17 days) and PK4 (206±40 days)...
October 28, 2016: Transplantation
https://www.readbyqxmd.com/read/27797585/beneficial-effects-of-everolimus-on-autism-and-attention-deficit-hyperactivity-disorder-symptoms-in-a-group-of-patients-with-tuberous-sclerosis-complex
#12
Ayse Kilincaslan, Burcu Ece Kok, Pinar Tekturk, Cengiz Yalcinkaya, Cigdem Ozkara, Zuhal Yapici
OBJECTIVES: Such neuropsychiatric symptoms as autism spectrum disorders, attention-deficit/hyperactivity disorder (ADHD), intellectual disability, aggression, and epilepsy are very common in patients with tuberous sclerosis complex (TSC). Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is a recent and effective treatment for TSC patients with giant cell astrocytomas and renal angiomyolipoma, and it has been shown to have a potential to reduce tumor volume. However, there is a paucity of studies on the effects of everolimus on neuropsychiatric symptoms...
October 31, 2016: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/27681252/is-bioresorbable-vascular-scaffold-acute-recoil-affected-by-baseline-renal-function-and-scaffold-selection
#13
Haci Murat Gunes, Filiz Kizilirmak Yılmaz, Tayyar Gokdeniz, Gultekin Gunhan Demir, Ekrem Guler, Gamze Babur Guler, Oğuz Karaca, Beytullah Cakal, Ersin İbişoğlu, Bilal Boztosun
OBJECTIVE: The aim of the present study was to investigate the relationship between glomerular filtration rate (GFR) and acute post-scaffold recoil (PSR) in patients undergoing bioresorbable scaffold (BVS) implantation. METHODS: We included 130 patients who underwent everolimus-eluting BVS device (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) or the novolimus-eluting BVS device (Elixir Medical Corporation) implantations for single or multi-vessel disease. Clinical, angiographic variables and procedural characteristics were defined and pre-procedural GFR was calculated for each patient...
September 20, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27680407/open-label-phase-2-trial-of-first-line-everolimus-monotherapy-in-patients-with-papillary-metastatic-renal-cell-carcinoma-raptor-final-analysis
#14
Bernard Escudier, Vincent Molinie, Sergio Bracarda, Pablo Maroto, Cezary Szczylik, Paul Nathan, Sylvie Negrier, Claudia Weiss, Camillo Porta, Viktor Grünwald, Laurence Albiges
BACKGROUND: Papillary histology accounts for 10-15% of renal cell carcinoma (RCC), and treatment options for patients with this subtype are limited. The RAPTOR (RAD001 in Advanced Papillary Tumor Program in Europe; ClinicalTrials.gov, NCT00688753) study evaluated first-line everolimus in patients with papillary metastatic RCC (mRCC). METHODS: This phase 2 trial enrolled previously untreated patients with type 1 or type 2 papillary mRCC. Papillary histology was confirmed by central review and was performed for every patient...
September 24, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27680012/abnormal-serum-microrna-profiles-in-tuberous-sclerosis-are-normalized-during-treatment-with-everolimus-possible-clinical-implications
#15
Joanna Trelinska, Wojciech Fendler, Iwona Dachowska, Katarzyna Kotulska, Sergiusz Jozwiak, Karolina Antosik, Piotr Gnys, Maciej Borowiec, Wojciech Mlynarski
BACKGROUND: Tuberous sclerosis (TSC) is a monogenic disease resulting from defects of the TSC1 or TSC2 genes, which encode the proteins forming hamartin-tuberin tumor suppressor complex, the mammalian target of rapamycin complex (mTOR). The mTOR pathway is constitutively activated in response to tuberin or hamartin defects. The mTOR pathway is also regulated by a multitude of epigenetic mechanisms, one of which is regulation by microRNA (miRNA) inhibition. This leads us to hypothesize that organ-level abnormalities of miRNA expression patterns are widespread in TSC...
September 29, 2016: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/27669821/everolimus-safety-and-efficacy-for-renal-angiomyolipomas-associated-with-tuberous-sclerosis-complex-a-spanish-expanded-access-trial
#16
Nicolás Roberto Robles, Ramón Peces, Álvaro Gómez-Ferrer, Felipe Villacampa, Jose Luis Álvarez-Ossorio, Pedro Pérez-Segura, Juan Morote, Bernardo Herrera-Imbroda, Javier Nieto, Joaquín Carballido, Urbano Anido, Marian Valero, Cristina Meseguer, Roser Torra
BACKGROUND: Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC) that may cause aneurism-related haemorrhages and renal impairment. Everolimus has emerged as an alternative to surgery/embolization. We provide further insight into everolimus safety and efficacy for TSC-related AML. METHODS: This was a Spanish expanded access trial including patients aged ≥18 years with TSC-related AML. They received 10 mg everolimus once daily until AML progression, unacceptable toxicity, death/withdrawal, commercialisation for TSC-related AML, or 1 year after first patient enrolment...
September 26, 2016: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/27639993/pancreatic-tumors-in-children-and-young-adults-with-tuberous-sclerosis-complex
#17
Gonca Koc, Sam Sugimoto, Rachel Kuperman, Bamidele F Kammen, S Pinar Karakas
BACKGROUND: Pancreatic neuroendocrine tumors are not included in the diagnostic criteria for tuberous sclerosis complex, although an association has been described. OBJECTIVE: To investigate the association of pancreatic neuroendocrine tumor in children and young adults with tuberous sclerosis complex and define MRI characteristics of the tumor. MATERIALS AND METHODS: We retrospectively evaluated the abdominal MRI scans of 55 children and young adults with tuberous sclerosis complex for the presence of a pancreatic mass...
September 17, 2016: Pediatric Radiology
https://www.readbyqxmd.com/read/27639176/incidence-of-bk-virus-infection-after-kidney-transplantation-is-independent-of-type-of-immunosuppressive-therapy
#18
Josephine Radtke, Nina Dietze, Lutz Fischer, Eike-Gert Achilles, Jun Li, Silke Scheidat, Friedrich Thaiss, Bjoern Nashan, Martina Koch
BACKGROUND: BK polyomavirus (BKV) infection and BKV nephropathy (BKVN) are risk factors for allograft function and survival. METHODS: We retrospectively analyzed BK viremia and BKVN in 348 patients who received a kidney transplantation donated after brain death (n=232) or living donation (n=116) between 2008 and 2013. A total of 266 patients were treated with standard immunosuppression consisting of basiliximab induction, calcineurin inhibitor (CNI), and mycophenolic acid (MPA, n=219) or everolimus (n=47); 82 patients received more intense immunosuppression with lymphocyte depletion, CNI and MPA (n=38) or everolimus (n=44)...
September 17, 2016: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/27634828/prospective-randomized-comparison-of-clinical-and-angiographic-outcomes-between-everolimus-eluting-vs-zotarolimus-eluting-stents-for-treatment-of-coronary-restenosis-in-drug-eluting-stents-intravascular-ultrasound-volumetric-analysis-restent-isr-trial
#19
Soon Jun Hong, Chul Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Seung-Ho Hur, Cheol Woong Yu, Seung-Jin Lee, Cheol Ung Choi, Je Sang Kim, Jung-Han Yoon, Young Joon Hong, Jae-Woong Choi, Seung-Hyuk Choi, Yangsoo Jang, Do-Sun Lim
AIMS: At present no proven standard treatment for drug-eluting stent (DES) restenosis is available, and the efficacy and safety of everolimus-eluting stent (EES) and zotarolimus-eluting stent (ZES) for DES restenosis are limited. The purpose of this prospective, randomized 9-month intracoronary ultrasound (IVUS) and 3-year clinical follow-up study was to compare the effects of EESs and ZESs on neointima volume and major adverse cardiovascular events (MACEs) such as death, myocardial infarction (MI), target lesion revascularization (TLR) and stent thrombosis in DES restenosis patients...
September 15, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27613521/adjunctive-everolimus-therapy-for-treatment-resistant-focal-onset-seizures-associated-with-tuberous-sclerosis-exist-3-a-phase-3-randomised-double-blind-placebo-controlled-study
#20
Jacqueline A French, John A Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Paolo Curatolo, Petrus J de Vries, Dennis J Dlugos, Noah Berkowitz, Maurizio Voi, Severine Peyrard, Diana Pelov, David N Franz
BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used for various benign tumours associated with tuberous sclerosis complex. We assessed the efficacy and safety of two trough exposure concentrations of everolimus, 3-7 ng/mL (low exposure) and 9-15 ng/mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous sclerosis complex. METHODS: In this phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 years with tuberous sclerosis complex and treatment-resistant seizures (≥16 in an 8-week baseline phase) receiving one to three concomitant antiepileptic drugs were recruited from 99 centres across 25 countries...
September 6, 2016: Lancet
keyword
keyword
50383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"